Human lactobacilli as supplementation of clindamycin to patients with bacterial vaginosis reduce the recurrence rate; a 6-month, double-blind, randomized, placebo-controlled ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2008-01-15

AUTHORS

Per-Göran Larsson, Babill Stray-Pedersen, Kjeld R Ryttig, Stig Larsen

ABSTRACT

BackgroundThe primary objective of this study was to investigate if supplementary lactobacilli treatment could improve the initial cure rate after vaginal clindamycin therapy, and secondly, if lactobacilli as repeated adjunct treatment during 3 menstrual cycles could lengthen the time to relapse after initial cure.MethodsWomen (n = 100) with bacterial vaginosis diagnosed by Amsel criteria were after informed consent offered vaginal clindamycin therapy followed by vaginal gelatine capsules containing either 109 freeze-dried lactobacilli or identical placebo capsules for 10 days during 3 menstrual cycles in a double-blind, randomized, placebo-controlled trial.ResultsThe initial intent to treat (ITT) analysis for the one-month cure rate was 64% in the lactobacilli group and 78% in the placebo group (p > 0.05). However, any patient with missing or unclassified smears at the initial visit who continued the study and whose next smear indicated a cure was included in the cured group; the study also excluded two of the patients in the lactobacilli group who reported that they did not take any vaginal capsules. With consideration to these population changes, the initial cure rate would be 77% in the lactobacilli group. The 76 cured women were followed for 6 menstrual cycles or until relapse within that time span. At the end of the study, 64.9% (24/37) of the lactobacilli treated women were still BV-free compared to 46.2% (18/39) of the placebo treated women. Comparison of the two groups regarding "Time from cure to relapse" was statistically significant (p = 0.027) in favour of the lactobacilli treatment. Adjuvant therapy with lactobacilli contributed significantly to avoidance of relapse with a proportional Hazard Risk ratio (HR) of 0.73 (0.54–0.98) (p < 0.05)ConclusionThe study shows that supplementary treatment combining two different strains of probiotic lactobacilli does not improve the efficacy of BV therapy during the first month of treatment, but for women initially cured, adjunct treatment of lactobacilli during 3 menstrual cycles lengthens the time to relapse significantly in that more women remained BV free at the end of the 6-month follow up.Trial registration numberISRCTN62879834 More... »

PAGES

3

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1472-6874-8-3

DOI

http://dx.doi.org/10.1186/1472-6874-8-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1005792714

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/18197974


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Intravaginal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Bacterial Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clindamycin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Combined Modality Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Confidence Intervals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lactobacillus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Norway", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Odds Ratio", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Probiotics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Secondary Prevention", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vagina", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vaginosis, Bacterial", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Women's Health", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Obstetrics and Gynaecology, K\u00e4rnsjukhuset, SE-541 85, Sk\u00f6vde, Sweden", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Obstetrics and Gynaecology, K\u00e4rnsjukhuset, SE-541 85, Sk\u00f6vde, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Larsson", 
        "givenName": "Per-G\u00f6ran", 
        "id": "sg:person.012634564012.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012634564012.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Obstetrics and Gynaecology, University of Oslo, Norway Rikshospitalet/Radiumhospitalet, Oslo, Norway", 
          "id": "http://www.grid.ac/institutes/grid.5510.1", 
          "name": [
            "Department of Obstetrics and Gynaecology, University of Oslo, Norway Rikshospitalet/Radiumhospitalet, Oslo, Norway"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stray-Pedersen", 
        "givenName": "Babill", 
        "id": "sg:person.0631122174.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0631122174.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Farmaservice, DK-2990, Niv\u00e5, Denmark", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Farmaservice, DK-2990, Niv\u00e5, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ryttig", 
        "givenName": "Kjeld R", 
        "id": "sg:person.010725643124.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010725643124.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Norwegian School of Veterinary Science, also Ullev\u00e5l University Hospital, Oslo, Norway", 
          "id": "http://www.grid.ac/institutes/grid.19477.3c", 
          "name": [
            "Norwegian School of Veterinary Science, also Ullev\u00e5l University Hospital, Oslo, Norway"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Larsen", 
        "givenName": "Stig", 
        "id": "sg:person.013272512512.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013272512512.34"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2008-01-15", 
    "datePublishedReg": "2008-01-15", 
    "description": "BackgroundThe primary objective of this study was to investigate if supplementary lactobacilli treatment could improve the initial cure rate after vaginal clindamycin therapy, and secondly, if lactobacilli as repeated adjunct treatment during 3 menstrual cycles could lengthen the time to relapse after initial cure.MethodsWomen (n = 100) with bacterial vaginosis diagnosed by Amsel criteria were after informed consent offered vaginal clindamycin therapy followed by vaginal gelatine capsules containing either 109 freeze-dried lactobacilli or identical placebo capsules for 10 days during 3 menstrual cycles in a double-blind, randomized, placebo-controlled trial.ResultsThe initial intent to treat (ITT) analysis for the one-month cure rate was 64% in the lactobacilli group and 78% in the placebo group (p > 0.05). However, any patient with missing or unclassified smears at the initial visit who continued the study and whose next smear indicated a cure was included in the cured group; the study also excluded two of the patients in the lactobacilli group who reported that they did not take any vaginal capsules. With consideration to these population changes, the initial cure rate would be 77% in the lactobacilli group. The 76 cured women were followed for 6 menstrual cycles or until relapse within that time span. At the end of the study, 64.9% (24/37) of the lactobacilli treated women were still BV-free compared to 46.2% (18/39) of the placebo treated women. Comparison of the two groups regarding \"Time from cure to relapse\" was statistically significant (p = 0.027) in favour of the lactobacilli treatment. Adjuvant therapy with lactobacilli contributed significantly to avoidance of relapse with a proportional Hazard Risk ratio (HR) of 0.73 (0.54\u20130.98) (p < 0.05)ConclusionThe study shows that supplementary treatment combining two different strains of probiotic lactobacilli does not improve the efficacy of BV therapy during the first month of treatment, but for women initially cured, adjunct treatment of lactobacilli during 3 menstrual cycles lengthens the time to relapse significantly in that more women remained BV free at the end of the 6-month follow up.Trial registration numberISRCTN62879834", 
    "genre": "article", 
    "id": "sg:pub.10.1186/1472-6874-8-3", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1028438", 
        "issn": [
          "1472-6874"
        ], 
        "name": "BMC Women's Health", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "8"
      }
    ], 
    "keywords": [
      "hazard risk ratio", 
      "initial cure rate", 
      "menstrual cycle", 
      "cure rate", 
      "Lactobacillus treatment", 
      "clindamycin therapy", 
      "adjunct treatment", 
      "bacterial vaginosis", 
      "Lactobacillus group", 
      "identical placebo capsules", 
      "avoidance of relapse", 
      "placebo-controlled trial", 
      "placebo-controlled study", 
      "placebo capsules", 
      "placebo group", 
      "adjuvant therapy", 
      "initial visit", 
      "BV therapy", 
      "recurrence rate", 
      "Amsel criteria", 
      "risk ratio", 
      "vaginal capsules", 
      "supplementary treatment", 
      "therapy", 
      "first month", 
      "informed consent", 
      "relapse", 
      "patients", 
      "initial cure", 
      "women", 
      "more women", 
      "gelatine capsules", 
      "treatment", 
      "probiotic lactobacilli", 
      "vaginosis", 
      "cure", 
      "human lactobacilli", 
      "smears", 
      "Lactobacillus", 
      "capsule", 
      "primary objective", 
      "group", 
      "different strains", 
      "placebo", 
      "MethodsWomen", 
      "clindamycin", 
      "follow", 
      "study", 
      "trials", 
      "visits", 
      "supplementation", 
      "months", 
      "study show", 
      "efficacy", 
      "rate", 
      "initial intent", 
      "consent", 
      "days", 
      "time", 
      "criteria", 
      "intent", 
      "end", 
      "cycle", 
      "avoidance", 
      "strains", 
      "changes", 
      "BV", 
      "objective", 
      "favor", 
      "ratio", 
      "time span", 
      "comparison", 
      "analysis", 
      "span", 
      "consideration", 
      "population change", 
      "show"
    ], 
    "name": "Human lactobacilli as supplementation of clindamycin to patients with bacterial vaginosis reduce the recurrence rate; a 6-month, double-blind, randomized, placebo-controlled study", 
    "pagination": "3", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1005792714"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1472-6874-8-3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "18197974"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1472-6874-8-3", 
      "https://app.dimensions.ai/details/publication/pub.1005792714"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T16:58", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_469.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/1472-6874-8-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1472-6874-8-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1472-6874-8-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1472-6874-8-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1472-6874-8-3'


 

This table displays all metadata directly associated to this object as RDF triples.

246 TRIPLES      20 PREDICATES      122 URIs      114 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1472-6874-8-3 schema:about N18c1474a0648456785b77b2a6b3fdb76
2 N1aef857c325f454898a98db88f018516
3 N1d6ad1bb378e429f9a2c79f426597358
4 N2bf1b31316cb4b99b3f7d8af52c147a5
5 N3a98801d12a644edb2987c8777f26e77
6 N40e67b3ae3c44232938a64bda87ded30
7 N41f963d7f97e464f96c6e174a0bb866a
8 N640ad21ee54a44139b8f1f57f931d981
9 N79e5995e63b34c96986710dc7b765781
10 N7d0834ccc20b4795886c8d195ebec27e
11 N81ea5f9028d34e4a937bfb6a286430b1
12 N8b5f31b840954ae6bb5a6c5ba09d74b4
13 N95d04ed9089744329ce1e5fbdbcb7e0c
14 N9b368c0b6527458194bbf8d2c7cbb9f2
15 N9b7101cc15bd4bb1a5e4aeffdffefd25
16 Nbd9005be95e548f4b9786fec43c83e7f
17 Nc3f0055610934ea7b97448c2e56c6541
18 Nd5c7dcc0dc914511953fbbf4a08c2842
19 Ne452f448682c46f0980742fb31289f35
20 Neb1a18d6e1c14c8295046c8de9020be8
21 anzsrc-for:11
22 anzsrc-for:1103
23 schema:author Nb18e506d2c084301af56a464829ef9fa
24 schema:datePublished 2008-01-15
25 schema:datePublishedReg 2008-01-15
26 schema:description BackgroundThe primary objective of this study was to investigate if supplementary lactobacilli treatment could improve the initial cure rate after vaginal clindamycin therapy, and secondly, if lactobacilli as repeated adjunct treatment during 3 menstrual cycles could lengthen the time to relapse after initial cure.MethodsWomen (n = 100) with bacterial vaginosis diagnosed by Amsel criteria were after informed consent offered vaginal clindamycin therapy followed by vaginal gelatine capsules containing either 109 freeze-dried lactobacilli or identical placebo capsules for 10 days during 3 menstrual cycles in a double-blind, randomized, placebo-controlled trial.ResultsThe initial intent to treat (ITT) analysis for the one-month cure rate was 64% in the lactobacilli group and 78% in the placebo group (p > 0.05). However, any patient with missing or unclassified smears at the initial visit who continued the study and whose next smear indicated a cure was included in the cured group; the study also excluded two of the patients in the lactobacilli group who reported that they did not take any vaginal capsules. With consideration to these population changes, the initial cure rate would be 77% in the lactobacilli group. The 76 cured women were followed for 6 menstrual cycles or until relapse within that time span. At the end of the study, 64.9% (24/37) of the lactobacilli treated women were still BV-free compared to 46.2% (18/39) of the placebo treated women. Comparison of the two groups regarding "Time from cure to relapse" was statistically significant (p = 0.027) in favour of the lactobacilli treatment. Adjuvant therapy with lactobacilli contributed significantly to avoidance of relapse with a proportional Hazard Risk ratio (HR) of 0.73 (0.54–0.98) (p < 0.05)ConclusionThe study shows that supplementary treatment combining two different strains of probiotic lactobacilli does not improve the efficacy of BV therapy during the first month of treatment, but for women initially cured, adjunct treatment of lactobacilli during 3 menstrual cycles lengthens the time to relapse significantly in that more women remained BV free at the end of the 6-month follow up.Trial registration numberISRCTN62879834
27 schema:genre article
28 schema:isAccessibleForFree true
29 schema:isPartOf N0009f2f676554d268c643fa306f03788
30 N0b578535362c4b2fb79f1f0d4ce965c6
31 sg:journal.1028438
32 schema:keywords Amsel criteria
33 BV
34 BV therapy
35 Lactobacillus
36 Lactobacillus group
37 Lactobacillus treatment
38 MethodsWomen
39 adjunct treatment
40 adjuvant therapy
41 analysis
42 avoidance
43 avoidance of relapse
44 bacterial vaginosis
45 capsule
46 changes
47 clindamycin
48 clindamycin therapy
49 comparison
50 consent
51 consideration
52 criteria
53 cure
54 cure rate
55 cycle
56 days
57 different strains
58 efficacy
59 end
60 favor
61 first month
62 follow
63 gelatine capsules
64 group
65 hazard risk ratio
66 human lactobacilli
67 identical placebo capsules
68 informed consent
69 initial cure
70 initial cure rate
71 initial intent
72 initial visit
73 intent
74 menstrual cycle
75 months
76 more women
77 objective
78 patients
79 placebo
80 placebo capsules
81 placebo group
82 placebo-controlled study
83 placebo-controlled trial
84 population change
85 primary objective
86 probiotic lactobacilli
87 rate
88 ratio
89 recurrence rate
90 relapse
91 risk ratio
92 show
93 smears
94 span
95 strains
96 study
97 study show
98 supplementary treatment
99 supplementation
100 therapy
101 time
102 time span
103 treatment
104 trials
105 vaginal capsules
106 vaginosis
107 visits
108 women
109 schema:name Human lactobacilli as supplementation of clindamycin to patients with bacterial vaginosis reduce the recurrence rate; a 6-month, double-blind, randomized, placebo-controlled study
110 schema:pagination 3
111 schema:productId N25c922d91dcb4935bfe816ee02a4c4b5
112 N8abe7ddf53b449b8aec75b65770c59c5
113 N90ee1cfb01554390a278c8929555c821
114 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005792714
115 https://doi.org/10.1186/1472-6874-8-3
116 schema:sdDatePublished 2022-08-04T16:58
117 schema:sdLicense https://scigraph.springernature.com/explorer/license/
118 schema:sdPublisher Nbfd305cbf94c466ca21be9ef9d3667ed
119 schema:url https://doi.org/10.1186/1472-6874-8-3
120 sgo:license sg:explorer/license/
121 sgo:sdDataset articles
122 rdf:type schema:ScholarlyArticle
123 N0009f2f676554d268c643fa306f03788 schema:issueNumber 1
124 rdf:type schema:PublicationIssue
125 N0b578535362c4b2fb79f1f0d4ce965c6 schema:volumeNumber 8
126 rdf:type schema:PublicationVolume
127 N0ef0bbfee4c14598b4edcd1ad5998c50 rdf:first sg:person.013272512512.34
128 rdf:rest rdf:nil
129 N18c1474a0648456785b77b2a6b3fdb76 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Combined Modality Therapy
131 rdf:type schema:DefinedTerm
132 N1aef857c325f454898a98db88f018516 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Vaginosis, Bacterial
134 rdf:type schema:DefinedTerm
135 N1d6ad1bb378e429f9a2c79f426597358 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Double-Blind Method
137 rdf:type schema:DefinedTerm
138 N25c922d91dcb4935bfe816ee02a4c4b5 schema:name pubmed_id
139 schema:value 18197974
140 rdf:type schema:PropertyValue
141 N2bf1b31316cb4b99b3f7d8af52c147a5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Follow-Up Studies
143 rdf:type schema:DefinedTerm
144 N3a98801d12a644edb2987c8777f26e77 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Administration, Oral
146 rdf:type schema:DefinedTerm
147 N40e67b3ae3c44232938a64bda87ded30 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Female
149 rdf:type schema:DefinedTerm
150 N41f963d7f97e464f96c6e174a0bb866a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Women's Health
152 rdf:type schema:DefinedTerm
153 N640ad21ee54a44139b8f1f57f931d981 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Lactobacillus
155 rdf:type schema:DefinedTerm
156 N79e5995e63b34c96986710dc7b765781 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Middle Aged
158 rdf:type schema:DefinedTerm
159 N7d0834ccc20b4795886c8d195ebec27e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Odds Ratio
161 rdf:type schema:DefinedTerm
162 N81ea5f9028d34e4a937bfb6a286430b1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Norway
164 rdf:type schema:DefinedTerm
165 N8abe7ddf53b449b8aec75b65770c59c5 schema:name doi
166 schema:value 10.1186/1472-6874-8-3
167 rdf:type schema:PropertyValue
168 N8b5f31b840954ae6bb5a6c5ba09d74b4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Clindamycin
170 rdf:type schema:DefinedTerm
171 N90ee1cfb01554390a278c8929555c821 schema:name dimensions_id
172 schema:value pub.1005792714
173 rdf:type schema:PropertyValue
174 N95d04ed9089744329ce1e5fbdbcb7e0c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Secondary Prevention
176 rdf:type schema:DefinedTerm
177 N9b368c0b6527458194bbf8d2c7cbb9f2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Probiotics
179 rdf:type schema:DefinedTerm
180 N9b7101cc15bd4bb1a5e4aeffdffefd25 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Humans
182 rdf:type schema:DefinedTerm
183 Nb18e506d2c084301af56a464829ef9fa rdf:first sg:person.012634564012.84
184 rdf:rest Nf1ab896edf4841d7863a4775a3d2e5bf
185 Nbd9005be95e548f4b9786fec43c83e7f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Vagina
187 rdf:type schema:DefinedTerm
188 Nbfd305cbf94c466ca21be9ef9d3667ed schema:name Springer Nature - SN SciGraph project
189 rdf:type schema:Organization
190 Nc3f0055610934ea7b97448c2e56c6541 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Anti-Bacterial Agents
192 rdf:type schema:DefinedTerm
193 Nd156fd1d5bb244f49abe1779c6c20c35 rdf:first sg:person.010725643124.05
194 rdf:rest N0ef0bbfee4c14598b4edcd1ad5998c50
195 Nd5c7dcc0dc914511953fbbf4a08c2842 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Adult
197 rdf:type schema:DefinedTerm
198 Ne452f448682c46f0980742fb31289f35 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Confidence Intervals
200 rdf:type schema:DefinedTerm
201 Neb1a18d6e1c14c8295046c8de9020be8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Administration, Intravaginal
203 rdf:type schema:DefinedTerm
204 Nf1ab896edf4841d7863a4775a3d2e5bf rdf:first sg:person.0631122174.01
205 rdf:rest Nd156fd1d5bb244f49abe1779c6c20c35
206 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
207 schema:name Medical and Health Sciences
208 rdf:type schema:DefinedTerm
209 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
210 schema:name Clinical Sciences
211 rdf:type schema:DefinedTerm
212 sg:journal.1028438 schema:issn 1472-6874
213 schema:name BMC Women's Health
214 schema:publisher Springer Nature
215 rdf:type schema:Periodical
216 sg:person.010725643124.05 schema:affiliation grid-institutes:None
217 schema:familyName Ryttig
218 schema:givenName Kjeld R
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010725643124.05
220 rdf:type schema:Person
221 sg:person.012634564012.84 schema:affiliation grid-institutes:None
222 schema:familyName Larsson
223 schema:givenName Per-Göran
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012634564012.84
225 rdf:type schema:Person
226 sg:person.013272512512.34 schema:affiliation grid-institutes:grid.19477.3c
227 schema:familyName Larsen
228 schema:givenName Stig
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013272512512.34
230 rdf:type schema:Person
231 sg:person.0631122174.01 schema:affiliation grid-institutes:grid.5510.1
232 schema:familyName Stray-Pedersen
233 schema:givenName Babill
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0631122174.01
235 rdf:type schema:Person
236 grid-institutes:None schema:alternateName Department of Obstetrics and Gynaecology, Kärnsjukhuset, SE-541 85, Skövde, Sweden
237 Farmaservice, DK-2990, Nivå, Denmark
238 schema:name Department of Obstetrics and Gynaecology, Kärnsjukhuset, SE-541 85, Skövde, Sweden
239 Farmaservice, DK-2990, Nivå, Denmark
240 rdf:type schema:Organization
241 grid-institutes:grid.19477.3c schema:alternateName Norwegian School of Veterinary Science, also Ullevål University Hospital, Oslo, Norway
242 schema:name Norwegian School of Veterinary Science, also Ullevål University Hospital, Oslo, Norway
243 rdf:type schema:Organization
244 grid-institutes:grid.5510.1 schema:alternateName Department of Obstetrics and Gynaecology, University of Oslo, Norway Rikshospitalet/Radiumhospitalet, Oslo, Norway
245 schema:name Department of Obstetrics and Gynaecology, University of Oslo, Norway Rikshospitalet/Radiumhospitalet, Oslo, Norway
246 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...